DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» ATC code B01
ATC code B01
Deliverable 5.A Interim Report on the Study Results APPENDIX 2
Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients with Renal Dysfunction
Evaluating Onco-Geriatric Scores and Medication Risks to Improve Cancer Care for Older Patients
Presentazione Standard Di Powerpoint
Annex I Summary of Product Characteristics
Clexane® 2.000 IE – 10.000 IE / Clexane® Multidose 50.000 IE
4 Annex I Summary of Product Characteristics
Summary of Product Characteristics
STATIN ADHERENCE, UTILISATION, and PRESCRIBING PATTERNS Improving Effectiveness of Treatment
Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea
1 Fachinformation Lovenox (Entspricht Clexane)
View PDF(339.46 K)
Ethnicity-Specific Drug Safety Data in European Medicines Agency
Prescriptions of Direct Oral Anticoagulants in Patients Admitted
Bericht ATC-Code B01: Antithrombotische Mittel
Allgemeine Innere Medizin / Médecine Interne Générale Abstracts
Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
Top View
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Australian Statistics on Medicines 2009
Evaluation Einer Maßnahme Zur Erhöhung Der Arzneimitteltherapiesicherheit Bei Ambulanten Patienten
Cardiovascular Disease in Persons with Depressive and Anxiety Disorders
Time in Therapeutic Range and Outcomes After Warfarin Initiation In
Annex I Summary of Product Characteristics
4 Annex I Summary of Product Characteristics
CLEXANE® 2000 Anti-Xa IU/0.2Ml CLEXANE® 4000 Anti-Xa IU/0.4Ml CLEXANE® 6000 Anti-Xa IU/0.6Ml
Predicting Stroke Risk in Patients with Atrial Fibrillation Using Machine Learning
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
All-Cause Mortality, Cardiovascular Events, and Health Care Costs After
Exanta® 3 Mg/0.3 Ml Melagatran Solution for Injection
Clexane/Clexane Forte Pre-Filled Syringes
Depression & Metabolic Syndrome Vogelzangs, N
ATC Code Title
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
Drotrecogin Alfa - Drugbank
Australian Statistics on Medicines 2003
Annex I Annex I Summary of Product Characteristics
Adherence to Statin Treatment Following a Myocardial Infarction: an Italian Population-Based Survey